Jim Cramer on Vanda Pharmaceuticals: “I’m Going to Bless That One as Your Spec”

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is one of the stocks on Jim Cramer’s radar recently. When Cramer was asked about the stock toward the end of the lightning round, he said:

“Well, look, here’s the way I feel about Vanda. This is a spec, and it’s absolutely like when I say in How to Make Money in Any Market: you can have a spec. I’m going to bless that one as your spec.”

Photo by Joshua Mayo on Unsplash

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) develops and markets therapies for sleep, neurological, psychiatric, and inflammatory disorders. On August 28, the company announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for VGT-1849B, a selective JAK2 inhibitor developed to treat polycythemia vera. Polycythemia vera is a rare blood disorder in which the bone marrow produces too many red blood cells. VGT-1849B uses OliPass Peptide Nucleic Acid technology to improve cell permeability and RNA targeting.

While we acknowledge the risk and potential of VNDA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VNDA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.